Evidence map›Paper›PMID 40847760›Full record

ArticleCancer cytopathology2025

The utility of next-generation sequencing in metastatic prostate cancer FNA biopsies.

Deepika Sirohi, Chien-Kuang Cornelia Ding, Bradley A Stohr, Ronald Balassanian, Poonam Vohra, Rahul Aggarwal, Emily Chan, Nancy Y Greenland

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cytopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Deepika SirohiDepartment of Pathology, University of California, San Francisco, California, USA.
Chien-Kuang Cornelia DingDepartment of Pathology, University of California, San Francisco, California, USA.
Bradley A StohrDepartment of Pathology, University of California, San Francisco, California, USA.
Ronald BalassanianDepartment of Pathology, University of California, San Francisco, California, USA.ORCID 0000-0001-5756-9052
Poonam VohraDepartment of Pathology, University of California, San Francisco, California, USA.ORCID 0000-0002-6055-4465
Rahul AggarwalDepartment of Medicine, University of California, San Francisco, California, USA.
Emily ChanDepartment of Pathology, Stanford University, Stanford, California, USA.
Nancy Y GreenlandDepartment of Pathology, University of California, San Francisco, California, USA.ORCID 0000-0002-1783-1711

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrent American Society of Clinical Oncology guidelines state that patients with metastatic prostate cancer (MPC) should undergo germline and somatic DNA sequencing. The authors examined the utility of next-generation sequencing (NGS) on fine-needle aspiration (FNA) biopsies in which NGS was performed on cell block (CB) and/or smears.

methodsA retrospective review was performed of cytology cases with diagnosis of MPC either before and/or after NGS on FNA material. Clinical and NGS data were obtained from the medical record. Androgen receptor, NKX3.1, INSM1, synaptophysin, chromogranin, Rb, PTEN, and Ki67 immunohistochemical stains were performed on CB if not originally done.

resultsSlides and NGS data were available for 46 MPC FNA biopsies from 45 patients from 2015 to 2024. Metastatic sites included 20 lymph node, 12 liver, five lung, four soft tissue, two pleura, two bone, and one adrenal gland. Ten patients (22%) had change or potential change in therapy based on NGS results. For one patient with poorly differentiated carcinoma previously thought to be urothelial, a TMPRSS2:ERG fusion confirmed prostatic origin. NGS confirmed lung origin for one patient diagnosed initially as metastatic prostatic adenocarcinoma. For one patient, NGS demonstrated TP53 and RB1 mutations, supporting transformation to high-grade neuroendocrine carcinoma. Change or potential change in therapy was planned for two patients with CDK12 mutations, one with IDH1 mutation, three with BRCA2 mutations, and one with PTEN and TP53 mutations.

conclusionsNGS on cytology material showed diagnostic and therapeutic utility in a subset of patients, with 10 of 46 patients (22%) having a change or potential in therapy based on NGS results.

Indexed as

Biomarkers, TumorHigh-Throughput Nucleotide SequencingProstatic NeoplasmsAgedAged, 80 and overBiopsy, Fine-NeedleHumansMaleMiddle AgedMutationNeoplasm MetastasisRetrospective StudiesBiomarkers, Tumorfine‐needle aspiration biopsyhigh‐grade neuroendocrine carcinomametastatic prostate cancernext‐generation sequencingprostate

Identifiers

PMID40847760
PMCPMC12374259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.